Damora Therapeutics, Inc. Ordinary Shares

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics granted inducement equity awards to five newly hired, non-executive employees on October 1, 2026, under Nasdaq Listing Rule 5635(c)(4). The grants are options to purchase 144,400 ordinary shares with a 10-year term and a $21.28 exercise price, vesting 25% at the one-year anniversary and monthly over the following 36 months. The disclosure is routine and administrative; it does not affect the company's clinical pipeline or capital position.

•0mo ago

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics granted inducement equity awards to three newly-hired, non-executive employees on September 1, 2026, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The awards are options to purchase an aggregate of 135,400 ordinary shares with a 10-year term and an exercise price of $28.18 per share, vesting 25% on the first anniversary of each hire's start date and in equal monthly installments over the following 36 months. Damora is a Boston-based biotechnology company developing biologics for mutant calreticulin-driven myeloproliferative neoplasms, with programs on track to enter clinical development in 2026.

•1mo ago

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics granted inducement equity awards to six newly hired non-executive employees effective August 1, 2026. The awards consist of options to purchase an aggregate of 451,000 ordinary shares at an exercise price of $28.99 per share. The options have a 10-year term and vest 25% on the first anniversary of the employees' start date, with the remaining portion vesting monthly over the following 36 months.

•2mo ago

Damora Announces Redomestication from Delaware to Cayman Islands

Damora Therapeutics completed its redomestication from the State of Delaware to the Cayman Islands, effective July 16, 2026, following shareholder approval in February. All outstanding common and preferred shares converted on a one-for-one basis, with the Nasdaq ticker symbol remaining DMRA. A new CUSIP (G2646Y104) becomes effective on July 20, 2026, though the company stated the move will not impact its business, management, or assets.

•3mo ago

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics granted inducement stock options to nine newly hired non-executive employees on July 1, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards cover an aggregate of 453,500 shares of common stock with a 10-year term and an exercise price of $26.01 per share. Options vest 25% on the first anniversary of the start date, with the remainder vesting in equal monthly installments over the following 36 months.

•4mo ago

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics granted inducement stock options to two newly hired non-executive employees as a material inducement to employment. The grants cover an aggregate of 57,500 shares with a 10-year term and an exercise price of $25.66 per share. Vesting occurs as to 25% on the first anniversary and in equal monthly installments over the following 36 months.

•6mo ago